secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001437749-25-024487
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex issues 2025 corporate update; two lung cancer trials ongoing
--------------------------------------------------------------------

- Patient treatment continues in two lung cancer clinical trials.
- Company highlights clinical milestones across oncology and diabetes programs.
- CEO Ryan Confer cites progress and upcoming milestones for H2 2025 and beyond.
- No specific financial results or enrollment numbers disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/0001437749-25-024487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/gnpx20250618d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer